318 related articles for article (PubMed ID: 27036972)
1. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
Mellman I; Hubbard-Lucey VM; Tontonoz MJ; Kalos MD; Chen DS; Allison JP; Drake CG; Levitsky H; Lonberg N; van der Burg SH; Fearon DT; Wherry EJ; Lowy I; Vonderheide RH; Hwu P
Cancer Immunol Res; 2016 Apr; 4(4):279-88. PubMed ID: 27036972
[TBL] [Abstract][Full Text] [Related]
2. A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics.
Costa MJ; Kudaravalli J; Liu WH; Stock J; Kong S; Liu SH
PLoS One; 2018; 13(3):e0194688. PubMed ID: 29554149
[TBL] [Abstract][Full Text] [Related]
3. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
Martinez Forero I; Okada H; Topalian SL; Gajewski TF; Korman AJ; Melero I
J Transl Med; 2012 May; 10():108. PubMed ID: 22640522
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy as an Option for Cancer Treatment.
Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
[TBL] [Abstract][Full Text] [Related]
5. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?
Perez-Gracia JL; Berraondo P; Martinez-Forero I; Alfaro C; Suarez N; Gurpide A; Sangro B; Hervas-Stubbs S; Ochoa C; Melero JA; Melero I
Immunotherapy; 2009 Sep; 1(5):845-53. PubMed ID: 20636027
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines: translation from mice to human clinical trials.
Maeng H; Terabe M; Berzofsky JA
Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development.
Sharon E; Polley MY; Bernstein MB; Ahmed M
Radiat Res; 2014 Aug; 182(2):252-7. PubMed ID: 25003314
[TBL] [Abstract][Full Text] [Related]
9. Approaches to improve development methods for therapeutic cancer vaccines.
Ogi C; Aruga A
Immunol Lett; 2015 Apr; 164(2):100-8. PubMed ID: 25746315
[TBL] [Abstract][Full Text] [Related]
10. [New directions in immunotherapy for malignant solid tumors].
Okuno K; Sugiura F; Sukegawa Y; Inoue K
Nihon Rinsho; 2012 Dec; 70(12):2075-86. PubMed ID: 23259377
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines: preclinical studies and novel strategies.
Palena C; Abrams SI; Schlom J; Hodge JW
Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
[TBL] [Abstract][Full Text] [Related]
12. Adapting Cancer Immunotherapy Models for the Real World.
Klevorn LE; Teague RM
Trends Immunol; 2016 Jun; 37(6):354-363. PubMed ID: 27105824
[TBL] [Abstract][Full Text] [Related]
13. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
14. New checkpoint inhibitors ride the immunotherapy tsunami.
Mullard A
Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
[No Abstract] [Full Text] [Related]
15. Therapeutic cancer vaccine development: will it ride the wave of new immunomodulatory agents?
Eggermont AM
Cancer J; 2011; 17(5):276. PubMed ID: 21952275
[No Abstract] [Full Text] [Related]
16. Design of clinical trials for therapeutic cancer vaccines development.
Mackiewicz J; Mackiewicz A
Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
[TBL] [Abstract][Full Text] [Related]
17. Report on the FDA-AACR Immuno-oncology Drug Development Workshop.
Curran C; Sharon E
Cancer Immunol Res; 2017 Apr; 5(4):282-285. PubMed ID: 28373216
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in therapeutic cancer vaccines.
Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
[TBL] [Abstract][Full Text] [Related]
20. [Cancer immunotherapy: recent breakthroughs and perspectives].
Tartour E; Sandoval F; Bonnefoy JY; Fridman WH
Med Sci (Paris); 2011 Oct; 27(10):833-41. PubMed ID: 22027420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
